RT @purviparwani: Great article on @jaccjournals on effect of PCSK9i on Lp(a) ➡PCSK9i caused 23% reduction in Lp(a) ⬇️in Lp(a) related to…
@renecardio4 @sigal_alan @LipidosSal @lynchsantiago @ferbotto @CardioBornan @lschreier1 @DanielPiskorz @alavallecobo @drdiegocosta @EmmanuelScatu Este es el de Odyssey tb sobre Lp(a) https://t.co/018lu1xaTo
🎉 Vera Bittner, MD, MSPH, has been included in the @ACCinTouch Top Picks for 2020 for her recent study on the effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome. https://t.co/xPencpVwgz @UABCardiology https://t.co
13/20 7-In FOURIER and Odyssey Outcomes, the highest quartile of Lp(a) was associated with highest risk in both studies 8-Alirocumab in OO reduced Lp(a)-mediated risk, accounting for nearly 1/3rd of the benefit noted in that study https://t.co/n0eRRQloBG
refs: https://t.co/dGeOMkIhBE, https://t.co/n0eRRQloBG, https://t.co/bVBbPrf7z4, https://t.co/cKpknX2sbL For a pt with Lp(a) 150 mg/dL, a 30% reduction with niacin is 45 mg/dl absolute, its in the ballpark for 20% RRR. Unfortunately we will never see such
RT @gabrielsteg: Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After A... https://t.co/m1GA4SES5z
RT @gabrielsteg: Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After A... https://t.co/m1GA4SES5z
RT @gabrielsteg: Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After A... https://t.co/m1GA4SES5z
RT @gabrielsteg: Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After A... https://t.co/m1GA4SES5z
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After A... https://t.co/m1GA4SES5z
Lower Lp(a) by Rx Matters! Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome https://t.co/E7iDvMM40c
RT @purviparwani: Great article on @jaccjournals on effect of PCSK9i on Lp(a) ➡PCSK9i caused 23% reduction in Lp(a) ⬇️in Lp(a) related to…
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. https://t.co/GC01NSQBMO
RT @Lpa_Doc: The Lp(a) ODYSSEY Outcomes paper is now out: https://t.co/HGaHuPkgqN. It concludes "Lipoprotein(a) lowering by alirocumab is a…
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome https://t.co/WmZF9GxUqv
RT @hcg_md: Targeting lipoprotein(a) might provide an additive benefit beyond LDL lowering, according to data from a prespecified sub-analy…
Targeting lipoprotein(a) might provide an additive benefit beyond LDL lowering, according to data from a prespecified sub-analysis ODYSSEY Outcomes - JACC https://t.co/z5fZlNh5fX
#PCSK9 inhibitors may have an added benefit by lowering LDL and fewer events, even in pts on high intensity chol lowering therapy. Lp a may also be a marker to target. Cool stuff! https://t.co/E2LynC4mIC
RT @UABCardiology: Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome https://t.co/jhDHFQPK7v
RT @Lpa_Doc: The Lp(a) ODYSSEY Outcomes paper is now out: https://t.co/HGaHuPkgqN. It concludes "Lipoprotein(a) lowering by alirocumab is a…
RT @Lpa_Doc: The Lp(a) ODYSSEY Outcomes paper is now out: https://t.co/HGaHuPkgqN. It concludes "Lipoprotein(a) lowering by alirocumab is a…
Thanks for this share!
RT @purviparwani: Great article on @jaccjournals on effect of PCSK9i on Lp(a) ➡PCSK9i caused 23% reduction in Lp(a) ⬇️in Lp(a) related to…
As a primary care #lifestylemedicine and #integrativemedicine physician, I read this article differently. There is STILL a residual risk (85%) that is not treated by a fancy expensive drug. Proof that drugs are not enough, and that lifestyle is critical. #
RT @purviparwani: Great article on @jaccjournals on effect of PCSK9i on Lp(a) ➡PCSK9i caused 23% reduction in Lp(a) ⬇️in Lp(a) related to…
RT @purviparwani: Great article on @jaccjournals on effect of PCSK9i on Lp(a) ➡PCSK9i caused 23% reduction in Lp(a) ⬇️in Lp(a) related to…
RT @purviparwani: Great article on @jaccjournals on effect of PCSK9i on Lp(a) ➡PCSK9i caused 23% reduction in Lp(a) ⬇️in Lp(a) related to…
RT @purviparwani: Great article on @jaccjournals on effect of PCSK9i on Lp(a) ➡PCSK9i caused 23% reduction in Lp(a) ⬇️in Lp(a) related to…
RT @purviparwani: Great article on @jaccjournals on effect of PCSK9i on Lp(a) ➡PCSK9i caused 23% reduction in Lp(a) ⬇️in Lp(a) related to…
RT @purviparwani: Great article on @jaccjournals on effect of PCSK9i on Lp(a) ➡PCSK9i caused 23% reduction in Lp(a) ⬇️in Lp(a) related to…
RT @purviparwani: Great article on @jaccjournals on effect of PCSK9i on Lp(a) ➡PCSK9i caused 23% reduction in Lp(a) ⬇️in Lp(a) related to…
Great article on @jaccjournals on effect of PCSK9i on Lp(a) ➡PCSK9i caused 23% reduction in Lp(a) ⬇️in Lp(a) related to ⬇️CVRisk independent of the concurrent reduction of other atherogenic lipoproteins. Lp(a)-> prognostic factor in pts with ACS ht
RT @SijunKimCV: Pre-specified analysis of ODYSSEY showed Lp(a) lowering w/ alirocumab reduces MACE, independent of concurrent LDL-C reduct.…
RT @SijunKimCV: Pre-specified analysis of ODYSSEY showed Lp(a) lowering w/ alirocumab reduces MACE, independent of concurrent LDL-C reduct.…
RT @skathire: Article: https://t.co/CS1O5WXUwY
RT @SijunKimCV: Pre-specified analysis of ODYSSEY showed Lp(a) lowering w/ alirocumab reduces MACE, independent of concurrent LDL-C reduct.…
RT @SijunKimCV: Pre-specified analysis of ODYSSEY showed Lp(a) lowering w/ alirocumab reduces MACE, independent of concurrent LDL-C reduct.…
RT @Lpa_Doc: The Lp(a) ODYSSEY Outcomes paper is now out: https://t.co/HGaHuPkgqN. It concludes "Lipoprotein(a) lowering by alirocumab is a…
RT @SijunKimCV: Pre-specified analysis of ODYSSEY showed Lp(a) lowering w/ alirocumab reduces MACE, independent of concurrent LDL-C reduct.…
Pre-specified analysis of ODYSSEY showed Lp(a) lowering w/ alirocumab reduces MACE, independent of concurrent LDL-C reduct. This was esp true when baseline Lp(a) conc were high. https://t.co/Od03dThxok #NYPQueens, #Echofirst, #JACC, @DLBHATTMD @gabrielsteg
RT @Lpa_Doc: The Lp(a) ODYSSEY Outcomes paper is now out: https://t.co/HGaHuPkgqN. It concludes "Lipoprotein(a) lowering by alirocumab is a…
RT @drmaggarwal: Great article by @VeraBittner2 @DLBHATTMD @gabrielsteg looking at the impact of Lp(a) on CV risk reduction independent of…
RT @drmaggarwal: Great article by @VeraBittner2 @DLBHATTMD @gabrielsteg looking at the impact of Lp(a) on CV risk reduction independent of…
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. https://t.co/idMaCMMqfP
RT @skathire: Article: https://t.co/CS1O5WXUwY
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. https://t.co/GC01NSQBMO
RT @Lpa_Doc: The Lp(a) ODYSSEY Outcomes paper is now out: https://t.co/HGaHuPkgqN. It concludes "Lipoprotein(a) lowering by alirocumab is a…
RT @drmaggarwal: Great article by @VeraBittner2 @DLBHATTMD @gabrielsteg looking at the impact of Lp(a) on CV risk reduction independent of…
RT @vass_vassiliou: Reduction of Lp(a) with #Alirocumab following ACS showed improved MACE @JACCJournals Time for a paradigm shift? Measure…
RT @drmaggarwal: Great article by @VeraBittner2 @DLBHATTMD @gabrielsteg looking at the impact of Lp(a) on CV risk reduction independent of…
RT @drmaggarwal: Great article by @VeraBittner2 @DLBHATTMD @gabrielsteg looking at the impact of Lp(a) on CV risk reduction independent of…
Great article by @VeraBittner2 @DLBHATTMD @gabrielsteg looking at the impact of Lp(a) on CV risk reduction independent of reduction of other lipoproteins. https://t.co/doAQMG5vzi https://t.co/w8ftr1795A
RT @vass_vassiliou: Reduction of Lp(a) with #Alirocumab following ACS showed improved MACE @JACCJournals Time for a paradigm shift? Measure…
Article: https://t.co/CS1O5WXUwY
In parallel publication in @JACCJournals I'm a simple #countrycardiologist, but can you say that reductions of LP(a) independently reduce MACE, simply from a subset analysis in the ODYSSEY Trial? https://t.co/mCyJXiPDRT
RT @gabrielsteg: Lp(a) reduction by Alirocumab was an independent contributor to event reduction after ACS in ODYSSEY OUTCOMES. https://t.…
RT @gabrielsteg: Lp(a) reduction by Alirocumab was an independent contributor to event reduction after ACS in ODYSSEY OUTCOMES. https://t.…
RT @TheFHFoundation: New @JACCJournals article highlights benefit of alirocumab in lowering lp(a). Study suggests lp(a) as independent cont…
RT @TheFHFoundation: New @JACCJournals article highlights benefit of alirocumab in lowering lp(a). Study suggests lp(a) as independent cont…
RT @JACCJournals: Lowering Lp(a) with alirocumab is an independent contributor to major adverse CV event reduction, suggesting an independe…
RT @TheFHFoundation: New @JACCJournals article highlights benefit of alirocumab in lowering lp(a). Study suggests lp(a) as independent cont…
RT @JACCJournals: Lowering Lp(a) with alirocumab is an independent contributor to major adverse CV event reduction, suggesting an independe…
RT @JACCJournals: Lowering Lp(a) with alirocumab is an independent contributor to major adverse CV event reduction, suggesting an independe…
RT @JACCJournals: Lowering Lp(a) with alirocumab is an independent contributor to major adverse CV event reduction, suggesting an independe…
RT @TheFHFoundation: New @JACCJournals article highlights benefit of alirocumab in lowering lp(a). Study suggests lp(a) as independent cont…
RT @vass_vassiliou: Reduction of Lp(a) with #Alirocumab following ACS showed improved MACE @JACCJournals Time for a paradigm shift? Measure…
RT @MAROSFO: Efectos de Alirocumab sobre Lp(a) tras SCA. Reducciones de Lp(a) con alirocumab reducen el riesgo CV independientemente del cL…
The era of Lp(a) coming? Lp(a) is an independent target apart from LDL.
RT @JACCJournals: Lowering Lp(a) with alirocumab is an independent contributor to major adverse CV event reduction, suggesting an independe…
RT @JACCJournals: Lowering Lp(a) with alirocumab is an independent contributor to major adverse CV event reduction, suggesting an independe…
RT @JACCJournals: Lowering Lp(a) with alirocumab is an independent contributor to major adverse CV event reduction, suggesting an independe…
RT @JACCJournals: Lowering Lp(a) with alirocumab is an independent contributor to major adverse CV event reduction, suggesting an independe…
New @JACCJournals article highlights benefit of alirocumab in lowering lp(a). Study suggests lp(a) as independent contributor to MACE reduction for individuals with acute coronary syndrome. #CVD #heartdisease #cardiotwitter https://t.co/zzs8p602hM https://
Lowering Lp(a) with alirocumab is an independent contributor to major adverse CV event reduction, suggesting an independent treatment target following #cvACS diagnosis. https://t.co/zSm8MZX4jo #JACC @gabrielsteg @DLBHATTMD https://t.co/3Rp7WwXEqa
RT @vass_vassiliou: Reduction of Lp(a) with #Alirocumab following ACS showed improved MACE @JACCJournals Time for a paradigm shift? Measure…
RT @vass_vassiliou: Reduction of Lp(a) with #Alirocumab following ACS showed improved MACE @JACCJournals Time for a paradigm shift? Measure…
RT @vass_vassiliou: Reduction of Lp(a) with #Alirocumab following ACS showed improved MACE @JACCJournals Time for a paradigm shift? Measure…
RT @Lpa_Doc: The Lp(a) ODYSSEY Outcomes paper is now out: https://t.co/HGaHuPkgqN. It concludes "Lipoprotein(a) lowering by alirocumab is a…
RT @vass_vassiliou: Reduction of Lp(a) with #Alirocumab following ACS showed improved MACE @JACCJournals Time for a paradigm shift? Measure…
RT @vass_vassiliou: Reduction of Lp(a) with #Alirocumab following ACS showed improved MACE @JACCJournals Time for a paradigm shift? Measure…
RT @MAROSFO: Efectos de Alirocumab sobre Lp(a) tras SCA. Reducciones de Lp(a) con alirocumab reducen el riesgo CV independientemente del cL…
Reduction of Lp(a) with #Alirocumab following ACS showed improved MACE @JACCJournals Time for a paradigm shift? Measure LP(a) in all ACS patients? https://t.co/1NcyETyNdQ But let’s not forget #healthydiet, #stopsmoking, #exercise @exerciseworks ALSO improv
#LPA *1-mg/dl reduction in lipoprotein(a) with alirocumab was associated with a HR of 0.994 (95% CI: 0.990 to 0.999)* https://t.co/OqEdiUDiLJ
RT @Lpa_Doc: The Lp(a) ODYSSEY Outcomes paper is now out: https://t.co/HGaHuPkgqN. It concludes "Lipoprotein(a) lowering by alirocumab is a…
RT @krychtiukmd: Lp(a) lowering via alirocumab is an independent contributor to MACE reduction after ACS - in the new @JACCJournals #Card…
RT @drbrowncares: #PrevCardioOnc @PrevCardioOnc
RT @pnatarajanmd: Every 1-mg/dl ↓ in Lp(a) with alirocumab associated with a HR of 0.994 (p = 0.0081) https://t.co/BHPu3RWsX2 @JACCJournals…
#PrevCardioOnc @PrevCardioOnc
RT @krychtiukmd: Lp(a) lowering via alirocumab is an independent contributor to MACE reduction after ACS - in the new @JACCJournals #Card…
RT @pnatarajanmd: Every 1-mg/dl ↓ in Lp(a) with alirocumab associated with a HR of 0.994 (p = 0.0081) https://t.co/BHPu3RWsX2 @JACCJournals…
RT @krychtiukmd: Lp(a) lowering via alirocumab is an independent contributor to MACE reduction after ACS - in the new @JACCJournals #Card…
RT @Lpa_Doc: The Lp(a) ODYSSEY Outcomes paper is now out: https://t.co/HGaHuPkgqN. It concludes "Lipoprotein(a) lowering by alirocumab is a…
RT @gabrielsteg: Lp(a) reduction by Alirocumab was an independent contributor to event reduction after ACS in ODYSSEY OUTCOMES. https://t.…
RT @MAROSFO: Efectos de Alirocumab sobre Lp(a) tras SCA. Reducciones de Lp(a) con alirocumab reducen el riesgo CV independientemente del cL…
RT @MAROSFO: Efectos de Alirocumab sobre Lp(a) tras SCA. Reducciones de Lp(a) con alirocumab reducen el riesgo CV independientemente del cL…
RT @krychtiukmd: Lp(a) lowering via alirocumab is an independent contributor to MACE reduction after ACS - in the new @JACCJournals #Card…
RT @krychtiukmd: Lp(a) lowering via alirocumab is an independent contributor to MACE reduction after ACS - in the new @JACCJournals #Card…
RT @krychtiukmd: Lp(a) lowering via alirocumab is an independent contributor to MACE reduction after ACS - in the new @JACCJournals #Card…